Photochemistry overcomes thermal limitations in the synthesis of 177Lu-labelled antibodies for radioimmunotherapy of gastric adenocarcinoma

The exquisite target selectivity of monoclonal antibodies (mAbs) makes them an attractive starting point for developing radiopharmaceuticals for applications in diagnostic imaging and molecularly targeted radio(immuno)therapy (RIT). Combining mAbs with therapeutic β − -emitting radionuclides like 177 Lu, offers ways to overcome drug resistance but radiosynthesis of 177 Lu-mAbs poses numerous chemical challenges. Classic 177 Lu-radiochemistry relies on high temperatures and prolonged reaction times to achieve quantitative labelling but this is incompatible with the regular approach of radiolabelling antibodies that are pre-functionalised with a metal ion free chelate. Here, photochemistry was used to produce 177 Lu-onartuzumab in <30 min which was subjected to an array of chemical, in vitro stability, cellular and in vivo tests using mouse models of human gastric adenocarcinoma. Pilot imaging and biodistribution analyses confirmed the tumour targeting specificity of 177 Lu-onartuzumab. In RIT experiments, intravenous administration of low activities of [ 177 Lu]Lu- 1 -onartuzumab (3.764 ± 0.079 MBq) to mice bearing MKN-45 subcutaneous xenografts, followed by temporal γ-ray imaging and ultrasound analysis demonstrated pronounced therapeutic response versus chemical dose and tumour growth control groups. Collectively, the experimental data, alongside retrospective dosimetry modelling, validated the photoradiosynthesis approach for creating viable, molecularly targeted 177 Lu-mAbs in a flash.

Authors

Institutions

Publication Details

Journal
npj Imaging
Published
2026-11-17
DOI
https://doi.org/10.1038/s44303-026-00205-3
Primary Topic
Radiopharmaceutical Chemistry and Applications
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Photochemistry overcomes thermal limitations in the synthesis of 177Lu-labelled antibodies for radioimmunotherapy of gastric adenocarcinoma

Jason P. Holland, Cesare Berton, Simon Klingler, Mirja Christine Nolff et al.
2 links
npj Imaging
Radiopharmaceutical Chemistry and Applications
article

Photochemistry overcomes thermal limitations in the synthesis of 177Lu-labelled antibodies for radioimmunotherapy of gastric adenocarcinoma

Jason P. Holland, Cesare Berton, Simon Klingler, Mirja Christine Nolff, Henrik Braband, Stanislav Prytuliak
article en

Abstract

The exquisite target selectivity of monoclonal antibodies (mAbs) makes them an attractive starting point for developing radiopharmaceuticals for applications in diagnostic imaging and molecularly targeted radio(immuno)therapy (RIT). Combining mAbs with therapeutic β − -emitting radionuclides like 177 Lu, offers ways to overcome drug resistance but radiosynthesis of 177 Lu-mAbs poses numerous chemical challenges. Classic 177 Lu-radiochemistry relies on high temperatures and prolonged reaction times to achieve quantitative labelling but this is incompatible with the regular approach of radiolabelling antibodies that are pre-functionalised with a metal ion free chelate. Here, photochemistry was used to produce 177 Lu-onartuzumab in <30 min which was subjected to an array of chemical, in vitro stability, cellular and in vivo tests using mouse models of human gastric adenocarcinoma. Pilot imaging and biodistribution analyses confirmed the tumour targeting specificity of 177 Lu-onartuzumab. In RIT experiments, intravenous administration of low activities of [ 177 Lu]Lu- 1 -onartuzumab (3.764 ± 0.079 MBq) to mice bearing MKN-45 subcutaneous xenografts, followed by temporal γ-ray imaging and ultrasound analysis demonstrated pronounced therapeutic response versus chemical dose and tumour growth control groups. Collectively, the experimental data, alongside retrospective dosimetry modelling, validated the photoradiosynthesis approach for creating viable, molecularly targeted 177 Lu-mAbs in a flash.

npj Imaging
University of Zurich (CH)
European Commission, Universität Zürich, Horizon 2020 Framework Programme
Good health and well-being
Radiopharmaceutical Chemistry and Applications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon